Local Drug Activation
Shasqi platform for local drug activation.
1. Local Biomaterial injection
Shasqi biomaterial is injected at the tumor site. The biomaterial contains activating agents that are inert in the body. These agents enable the concentration and activation of the full power of chemotherapy drugs directly at the tumor site.
2. ProDrug Dose
Patient receives a prodrug of an FDA-approved drug that has been molecularly modified. This moiety inactivates the drug and allows it to be locally concentrated around the biomaterial and tumor.
3. ProDrug Activation
Contact between the prodrug and biomaterial leads to the release of the active chemotherapy at the tumor site. Our preclinical studies show this approach increases efficacy bringing tumors to remission.
Our technology, based on bioorthogonal chemistry, enables the activation of small molecule drugs at the local tissue-level, improving both their efficacy and safety. The method is independent of endogenous cellular or environmental markers and allows the activation of drugs at a specific location for multiple weeks after the initial injection of the biomaterial at the desired site.
Local chemotherapy activation.
Highly modular drug delivery platform
New approach to validated cancer pathways
Compatible with many small molecule therapies
Allows concurrent use of multiple therapies
Shasqi has created a new way to deliver drugs in the body. Our proprietary local drug activation technology allows delivery of more drug to the tumor with fewer side effects.
10-day treatment course with Shasqi’s local activation technology leads to remission of soft tissue sarcoma tumors.
Major opportunity for combination therapies
Tumor remission after a single 10 day course
No tumor recurrence after 3 months
No weight loss at 3x MTD
No myelosuppression at 3x MTD
Protecting Healthy Cells
This drug delivery system focuses the drug in the desired tissue compartment, increasing efficacy and minimizing adverse events. The improved side effect profile can allow concurrent use of multiple cytotoxic drugs. The preservation of the immune function can allow concurrent use of immunotherapies.